MedTrace Logo

Immune Response of Visceral Leishmaniasis PatientsTreated With Antimonial Plus N-Acetylcysteine

NCT01138956 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2010-06-08

No results posted yet for this study

Summary

This study is designed to evaluate the immune and therapeutic responses of visceral leishmaniasis patients using N-acetylcysteine (NAC) as an adjuvant therapy to pentavalent antimony.

Conditions

  • Visceral Leishmaniasis
  • Immune Response
  • Treatment

Interventions

DRUG

N-acetylcysteine

N-acetylcysteine (NAC), effervescent tablets of 600mg, tid, po, 28 days

DRUG

Pentavalent antimonial

Pentavalent antimonial, 20mg/kg/day, 28 days, IV

Sponsors & Collaborators

  • Hospital Universitário Professor Edgard Santos

    lead OTHER

Principal Investigators

  • Roque P Almeida, MD, PhD · Hospital Universitário

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-06-30
Completion
2011-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01138956 on ClinicalTrials.gov